Skip to main content
. 2013 Apr;57(4):1701–1708. doi: 10.1128/AAC.00934-12

Fig 2.

Fig 2

The novel 3NI analog has enhanced antibacterial activity, particularly against P. aeruginosa, in comparison to the wild-type peptides. The antibacterial activities of wild-type hBD1 and hBD3, the analogs 1C, 3I, and 3N, and the novel analog 3NI were tested at two concentrations (2.5 and 12.5 μM) against P. aeruginosa (A), E. coli (B), and E. faecalis (C) with 0, 50, 100, and 200 mM NaCl. Error bars show the standard deviations (SDs) from three independent experiments.